AI Terminal
TRISTEL PLC
Report Publication Announcement • Oct 1, 2024
7990_rns_2024-10-01_6df3a9f2-a5f7-4d3e-abdc-b63d8ae955d1.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 3129G
Tristel PLC
01 October 2024
TRISTEL plc
("Tristel" or the "Company")
Notice of Preliminary Results
Investor presentations
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that its preliminary results for the year ended 30 June 2024 will be announced on Monday 21 October 2024.
Analyst briefing
A briefing open to analysts will take place in London on Monday 21 October 2024 at 10:00 BST. To register and for more details please contact Walbrook PR on [email protected]
Investor presentations
Matt Sassone, CEO, and Liz Dixon, CFO, will present the Company's results in two separate events open to all investors. The same presentation will be given at both events which are being held at different times to offer convenient options for those wishing to attend.
Two presentations will take place on Monday 21 October 2024 at the following times, the first will be held online via the Investor Meet Company platform and the second will be held in-person in the City of London, full details below:
1. Investor Meet Company online presentation
Tristel management will provide a live online presentation relating to the preliminary results via Investor Meet Company at 11:30 BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 BST the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Tristel plc via:
https://www.investormeetcompany.com/tristel-plc/register-investor
2. In-person investor presentation
Tristel management will provide an in-person presentation relating to the Company's preliminary results at 16:30 BST, which is open to all existing and potential shareholders. T he Company welcomes investors to 85 Gresham Street, London, EC2V 7NQ from 16:15 BST for a 16:30 BST start and will be followed by refreshments.
If you would like to attend, please contact Walbrook PR on 020 7933 8780 or email [email protected] .
The results presentation will be made available on the Company's website on the day of results www.investors.tristel.com
For further information please contact:
| Tristel plc | Via Walbrook PR |
| Matt Sassone, Chief Executive Officer | www.investors.tristel.com |
| Liz Dixon, Chief Financial Officer | |
| Walbrook PR Ltd | Tel: 02079338780 or [email protected] |
| Paul McManus / Alice Woodings | Mob: 07980 541 893 / 0 7407 804 654 |
| Cavendish Capital Markets Ltd | Tel: 020 7220 0500 |
| Geoff Nash / Camilla Hume / Trisyia Jamaludin (Corporate Finance) | |
| Sunila de Silva (ECM) / Louise Talbot (Sales) |
About Tristel plc
Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.
Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries. The Company targets annual revenue growth of between 10% and 15% and an EBITDA margin of at least 25% (targets to be updated in February 2024) and the business is profitable, with no debt and has a progressive dividend policy.
The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product range please visit: https://tristel.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORLMMATMTIJBJI